Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its expertise in biotechnology, drug delivery and central nervous system clinical development as the company advances its pipeline of novel serotonergic agonists. The additions support Helus Pharma's focus on disciplined, evidence-based drug development, including programs targeting major depressive disorder and generalized anxiety disorder, as it works to address unmet needs in mental health.
Dr. Robert Langer is a renowned figure in biotechnology and drug delivery, with over 1,500 issued and pending patents and numerous accolades, including the National Medal of Science and the Queen Elizabeth Prize for Engineering. His addition to the Scientific Advisory Board signals Helus Pharma's commitment to leveraging cutting-edge science in its development of novel serotonergic agonists (NSAs). Dr. Stephen Brannan brings extensive experience in CNS clinical development, having led programs at Sunovion Pharmaceuticals and served as Chief Medical Officer at multiple biotech firms. His expertise will be instrumental as Helus Pharma advances HLP003 and HLP004 through clinical trials.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004 is in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma maintains an extensive research portfolio of investigational NSAs.
The company operates in Canada, the United States, the United Kingdom and Ireland. For more information, visit the company's website at www.helus.com or follow on X, LinkedIn, YouTube and Instagram. The full press release is available at https://ibn.fm/CyjTq.
